Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024
November 08, 2017 18:45 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051
November 07, 2017 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
November 06, 2017 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Nationwide Children’s Hospital to initiate a Phase 1/2a clinical trial at potentially therapeutic doses in children with DMD by mid-November 2017 -- -- First micro-dystrophin gene therapy program...
Sarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program
November 03, 2017 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
November 01, 2017 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2017 18:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR/Cas9 Technology to Develop New Treatments for Duchenne Muscular Dystrophy (DMD)
October 31, 2017 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments
October 25, 2017 16:01 ET
|
Sarepta Therapeutics, Inc.
-- Third quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $46 million -- -- Company raises annual 2017 revenue guidance to between $150 million and $155 million -- CAMBRIDGE, Mass., Oct. ...
Sarepta Therapeutics to Announce Third Quarter 2017 Financial Results and Recent Corporate Developments on October 25, 2017
October 16, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2017 18:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...